Palbociclib was first approved in the United States in 2015 and was used in combination with letrozole to treat postmenopausal women with estrogen receptor (ER)-positive/HER-2 negative advanced breast cancer (Dhillon, 2015). Here, ERBB2 is linked to breast cancer.